Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

[1]  Y. Imai,et al.  Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses , 2010, Journal of viral hepatitis.

[2]  Y. Imai,et al.  Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders , 2010, Journal of viral hepatitis.

[3]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[4]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[5]  K. Reddy,et al.  Peginterferon alfa‐2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub‐sets of older and younger HCV genotype 1 patients , 2009, Journal of viral hepatitis.

[6]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[7]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[8]  D. Nelson,et al.  A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment‐naïve patients with chronic hepatitis C: ViSER1 results , 2009, Hepatology.

[9]  Y. Imai,et al.  Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[10]  Y. Imai,et al.  Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[11]  Yoshiyuki Suzuki,et al.  Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.

[12]  Y. Imai,et al.  Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[14]  M. Capobianchi,et al.  The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr , 2007, The American Journal of Gastroenterology.

[15]  N. Hayashi,et al.  Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[16]  田浦 直太.  Increasing Hepatitis C Virus-Associated Hepatocellular Carcinoma Mortality and Aging: Long Term Trends in Japan , 2006 .

[17]  Y. Shiratori,et al.  Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C , 2006, Hepatology.

[18]  Y. Imai,et al.  Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response , 2004, Journal of Gastroenterology.

[19]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[20]  Y. Imai,et al.  Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver‐related death , 2004, Journal of viral hepatitis.

[21]  H. Yoshizawa.  Trends of hepatitis virus carriers , 2002 .

[22]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[23]  K. Eguchi,et al.  Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C , 2002, Cancer.

[24]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  K. Chayama,et al.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis , 1999, Hepatology.

[26]  N. Hayashi,et al.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.

[27]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[28]  N. Hayashi,et al.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. , 1995, Journal of hepatology.

[29]  D. Harnois.  Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .

[30]  N. Hayashi,et al.  Antiviral therapy for chronic hepatitis C: past, present, and future , 2005, Journal of Gastroenterology.